ArticleFrontiers in oncology2022

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.

Qi Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.